<DOC>
	<DOCNO>NCT00539890</DOCNO>
	<brief_summary>To compare efficacy prandial TI plus basal insulin versus prandial rapid acting , subcutaneous insulin plus basal insulin subject type 2 diabetes HbA1c &gt; 7.0 % &lt; 11.5 % .</brief_summary>
	<brief_title>Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<criteria>At least 2 year since diagnosis type 2 diabetes mellitus Received subcutaneous ( sc ) insulin least 3 month Body Mass Index &lt; 44 kg/m2 HbA1c &gt; 7.0 % &lt; 11.5 % Serum creatinine &lt; 2.0 mg/dL male &lt; 1.8 mg/dL female Baseline FVC FEV1 &gt; 70 % &lt; 125 % predict normal Significant hepatic disease ( AST/ALT3 x ULN ) Diagnosis Type 1 diabetes Severe complication diabetes History moderate severe ketoacidosis within past 3 month Upper respiratory infection last 15 day low respiratory infection past 30 day Diagnosis HIV Positive serology hepatitis B C COPD , emphysema , asthma Current smoker smoke history within past 6 month Major psychiatric disorder preclude satisfactory completion protocol Clinically significant heart disease disease , stroke heart attack within past 6 month Treatment investigational drug within 30 day Previous treatment Technosphere/Insulin History malignancy past 5 year except basal cell carcinoma Anemia ( hemoglobin &lt; 10.5 g/dL female &lt; 11.5 g/dL ( male ) Women pregnant lactate History hypersensitivity drug resemble FDKP carrier product Treatment another inhaled insulin product duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>